Tris Pharma, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
17
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for GHB Pharmaceutical Compositions Comprising a Floating Interpenetrating Polymer Network Forming System (US 11,666,546) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 2 fees due May 10, 2027
- 1 fee due Jun 17, 2027The maintenance fee for Methylphenidate Extended Release Chewable Tablet (US 10,507,203) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Benzonatate Modified Release Solid Tablets and Capsules (US 11,890,267) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
- 3 fees due Sep 5 to 29, 2027 · next Sep 5
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,202,537 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes In force · High confidence | In force | High confidence | |
| US 8,337,890 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes In force · High confidence | In force | High confidence | |
| US 8,597,684 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes In force · High confidence | In force | High confidence | |
| US 8,747,902 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes In force · High confidence | In force | High confidence | |
| US 8,790,700 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes In force · High confidence | In force | High confidence | |
| US 8,883,217 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes In force · High confidence | In force | High confidence | |
| US 9,198,864 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes In force · High confidence | In force | High confidence | |
| US 9,549,989 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes In force · High confidence | In force | High confidence | |
| US 9,675,703 | Modified Release Formulations Containing Drug - Ion Exchange Resin Complexes In force · High confidence | In force | High confidence | |
| US 9,675,704 | Modified Release Formulations Containing Drug - Ion Exchange Resin Complexes In force · High confidence | In force | High confidence |
Also on record, not counted in the 55: 3 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 6 abandoned · 13 no status recorded